MAP3K8 and ulcerative colitis: It is worth noting that TPL2 inhibition also suppresses p105/p50 NF-κB activation [75], providing greater specificity to inhibitors, such as the TPL2 inhibitor GS-4875, currently being trialled for ulcerative colitis (ClinicalTrials.gov Identifier: NCT04130919).